Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Monopar Therapeutics Inc. is currently engaged in patent prosecution within the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions. Interestingly, both of these actions are being handled by 1 distinct examiner and are located within 1 distinct art unit, indicating a high level of concentration for the company's current intellectual property efforts.
The busiest examiner for Monopar Therapeutics Inc. is SCHLIENTZ, LEAH H, who is managing 2 pending office actions. This means that SCHLIENTZ, LEAH H is responsible for the entirety of the company's current pending workload at the patent office. For a practitioner, this concentration simplifies the point of contact but also means that success is heavily dependent on the specific examination style of this one individual.
With 1 distinct examiner, the company has a consistent point of interaction for its current filings. The involvement of only 1 distinct art unit further suggests that the technology being patented is specialized within the Biotechnology & Pharmaceuticals field. This lack of diversification across examiners or art units means that the prosecution strategy must be perfectly aligned with the expectations of SCHLIENTZ, LEAH H.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 2 | 41.9% | +38.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010510 | MATERIALS AND METHODS FOR TREATING CORONAVIRUS | SCHLIENTZ, LEAH H | — |
| 17749574 | Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use | SCHLIENTZ, LEAH H | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18010510 | MATERIALS AND METHODS FOR TREATING CORONAVIRUS | SCHLIENTZ, LEAH H | 1618 | §102§103§112DP | Final Rejection | — | Pending | Dec 15, 2022 |
| 17749574 | Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use | SCHLIENTZ, LEAH H | 1618 | §103Other | Final Rejection | — | Pending | May 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial